Taken together, our findings establish the involvement of the PRR in liver triglyceride synthesis and suggest the therapeutic potential of PRR antagonism for the treatment of liver steatosis and fibrosis in NAFLD. The gene discussed is ATP6AP2; the disease is metabolic dysfunction-associated steatotic liver disease.